COMP <GO>
DERM vs LLY // 10Y YIELD & FRED MACRO BETA
Journey Medical Corporation (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: DERM 0
— LLY 11
■ METRIC PARITY
LAST: $4.79 (-7.35%) • MKT CAP: $145.9M
macro-sensitivity
—
LAST: $1,410.99 (-0.46%) • MKT CAP: $1.33T
macro-sensitivity
0.51
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DERM VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DERM | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 65.80% | 83.64% | -17.84 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -19.50% | 32.36% | -51.86 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.15% | 2.30% | -10.45 | LLY | /fcf-yield <GO> |
| Operating Margin | -13.30% | 40.21% | -53.51 | LLY | /operating-margins <GO> |
| Net Profit Margin | -18.70% | 31.90% | -50.60 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 11.10% | 45.51% | -34.41 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.74 | 9.29 | -8.55 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.81% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.5 | 71.0 | -30.50 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 30.6x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $145.9M | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DERM REV | LLY REV | DERM GROSS % | LLY GROSS % | DERM FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $61.2M | $65.18B | 65.8% | 83.0% | -$12.4M | $16.81B |
| FY 2024 | $55.1M | $45.04B | 62.1% | 81.3% | -$9.1M | $8.82B |
| FY 2023 | $59.7M | $34.12B | — | 79.3% | $5.2M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DERM // BETA —
LLY // BETA 0.51